- See the difference! Customize Seeking Alpha: Sign in or join
Seeking Alpha
-
Monday, February 8th
Large Pharma and Small Biotech Deals Expected to Increase in 2010
-
GlaxoSmithKline, Poniard, Protalix Provide Biotech's Latest Mishaps
-
Sunday, February 7th
How Big Pharma Got in This Fix
-
Thursday, February 4th
Iron Safety Hits AMAG Pharmaceuticals
-
Pfizer's New Alzheimer's Drug: A Black Box Indeed
-
Labopharm Just Became a Great Growth Stock
-
Wednesday, February 3rd
NeoStem Taps Chinese Healthcare Reform Profits
-
3 Best Hedge Fund Healthcare Ideas
-
Novo Nordisk Has High Hopes for Diabetes Blockbuster
-
4 Companies Experiencing Speculative Option Activity
-
Tuesday, February 2nd
Cephalon: Long-Term Support Starting to Line Up
-
Another Setback for Protalix
-
GlaxoSmithKline's Malaria Database Deserves More Press
-
Cell Therapeutics: Worth Buying Ahead of FDA Decision
-
Ironwood Pharmaceuticals, Imperial Capital Test the IPO Waters
-
Pfizer Moves Toward Goal of Becoming Top-Tier Biotherapeutics Company
-
Dendreon: To Short or Not to Short?
-
Carl Icahn's Growing Biogen Front
-
In Cautionary Mode: Overweight Tech, Healthcare, Consumer Staples, Emerging / Frontier Markets
-
Monday, February 1st
Venture Financing Comes Through for Biotech
-
Ironwood Pharma: First Biotech IPO of 2010
-
Geron Explores New Application for Hampered Alzheimer's Drug
-
Novartis Makes Notable CEO Pick
-
Sunday, January 31st
AstraZeneca to Ax 8,000 More Workers: Biotech's Latest Mishaps
-
What the Uncertainty Surrounding Healthcare Reform Means for Follow-On Biologics